Non-HFE Hepatic Iron Overload

ABSTRACT

Numerous clinical entities have now been identified to cause pathologic iron accumulation in the liver. Some are well described and have a verified hereditary basis; in others the genetic basis is still speculative, while in several cases nongenetic iron-loading factors are apparent. The non-HFE hemochromatosis syndromes identifies a subgroup of hereditary iron loading disorders that share with classic HFE-hemochromatosis, the autosomal recessive trait, the pathogenic basis (i.e., lack of hepcidin synthesis or activity), and key clinical features. Yet, they are caused by pathogenic mutations in other genes, such as transferrin receptor 2 (TFR2), hepcidin (HAMP), hemojuvelin (HJV), and ferroportin (FPN), and, unlike HFE-hemochromatosis, are not restricted to Caucasians. Ferroportin disease, the most common non-HFE hereditary iron-loading disorder, is caused by a loss of iron export function of FPN resulting in early and preferential iron accumulation in Kupffer cells and macrophages with high ferritin levels and low-to-normal transferrin saturation. This autosomal dominant disorder has milder expressivity than hemochromatosis. Other much rarer genetic disorders are associated with hepatic iron load, but the clinical picture is usually dominated by symptoms and signs due to failure of other organs (e.g., anemia in atransferrinemia or neurologic defects in aceruloplasminemia). Finally, in the context of various necro-inflammatory or disease processes (i.e., chronic viral or metabolic liver diseases), regional or local iron accumulation may occur that aggravates the clinical course of the underlying disease or limits efficacy of therapy.

KEYWORDS

Iron overload - non-HFE hemochromatosis - transferrin receptor 2 - hepcidin - ferroportin - hemojuvelin

REFERENCES

• 1 Bothwell T H. The control of iron absorption.  Br J Haematol. 1968;  14 (5) 453-456
• 2 Pietrangelo A. Metals, oxidative stress, and hepatic fibrogenesis.  Semin Liver Dis. 1996;  16 (1) 13-30
• 3 Pietrangelo A. Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment.  Gastroenterology. 2010;  139 (2) 393-408, 408 e1-e2
• 4 Feder J N, Gnirke A, Thomas W et al.. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis.  Nat Genet. 1996;  13 (4) 399-408
• 5 Pietrangelo A. Hemochromatosis 1998: is one gene enough?.  J Hepatol. 1998;  29 (3) 502-509
• 6 Camaschella C, Roetto A, Calì A et al.. The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22.  Nat Genet. 2000;  25 (1) 14-15
• 7 Roetto A, Papanikolaou G, Politou M et al.. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis.  Nat Genet. 2003;  33 (1) 21-22
• 8 Papanikolaou G, Samuels M E, Ludwig E H et al.. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis.  Nat Genet. 2004;  36 (1) 77-82
• 9 Montosi G, Donovan A, Totaro A et al.. Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene.  J Clin Invest. 2001;  108 (4) 619-623
• 10 Pietrangelo A, Montosi G, Totaro A et al.. Hereditary hemochromatosis in adults without pathogenic mutations in the hemochromatosis gene.  N Engl J Med. 1999;  341 (10) 725-732
• 11 De Gobbi M, Barilaro M R, Garozzo G, Sbaiz L, Alberti F, Camaschella C. TFR2 Y250X mutation in Italy.  Br J Haematol. 2001;  114 (1) 243-244
• 12 Roetto A, Totaro A, Piperno A et al.. New mutations inactivating transferrin receptor 2 in hemochromatosis type 3.  Blood. 2001;  97 (9) 2555-2560
• 13 Girelli D, Bozzini C, Roetto A et al.. Clinical and pathologic findings in hemochromatosis type 3 due to a novel mutation in transferrin receptor 2 gene.  Gastroenterology. 2002;  122 (5) 1295-1302
• 14 Majore S, Milano F, Binni F et al.. Homozygous p.M172K mutation of the TFR2 gene in an Italian family with type 3 hereditary hemochromatosis and early onset iron overload.  Haematologica. 2006;  91 (8, Suppl) ECR33
• 15 Gérolami V, Le Gac G, Mercier L, Nezri M, Bergé-Lefranc J L, Férec C. Early-onset haemochromatosis caused by a novel combination of TFR2 mutations(p.R396X/c.1538-2 A> G) in a woman of Italian descent.  Haematologica. 2008;  93 (5) e45-e46
• 16 Mattman A, Huntsman D, Lockitch G et al.. Transferrin receptor 2 (TfR2) and HFE mutational analysis in non-C282Y iron overload: identification of a novel TfR2 mutation.  Blood. 2002;  100 (3) 1075-1077
• 17 Hattori A, Wakusawa S, Hayashi H et al.. AVAQ 594-597 deletion of the TfR2 gene in a Japanese family with hemochromatosis.  Hepatol Res. 2003;  26 (2) 154-156
• 18 Le Gac G, Mons F, Jacolot S, Scotet V, Férec C, Frébourg T. Early onset hereditary hemochromatosis resulting from a novel TFR2 gene nonsense mutation (R105X) in two siblings of north French descent.  Br J Haematol. 2004;  125 (5) 674-678
• 19 Koyama C, Wakusawa S, Hayashi H et al.. Two novel mutations, L490R and V561X, of the transferrin receptor 2 gene in Japanese patients with hemochromatosis.  Haematologica. 2005;  90 (3) 302-307
• 20 Lee P L, Barton J C. Hemochromatosis and severe iron overload associated with compound heterozygosity for TFR2 R455Q and two novel mutations TFR2 R396X and G792R.  Acta Haematol. 2006;  115 (1–2) 102-105
• 21 Hsiao P J, Tsai K B, Shin S J et al.. A novel mutation of transferrin receptor 2 in a Taiwanese woman with type 3 hemochromatosis.  J Hepatol. 2007;  47 (2) 303-306
• 22 Biasiotto G, Belloli S, Ruggeri G et al.. Identification of new mutations of the HFE, hepcidin, and transferrin receptor 2 genes by denaturing HPLC analysis of individuals with biochemical indications of iron overload.  Clin Chem. 2003;  49 (12) 1981-1988
• 23 Pelucchi S, Mariani R, Trombini P et al.. Expression of hepcidin and other iron-related genes in type 3 hemochromatosis due to a novel mutation in transferrin receptor-2.  Haematologica. 2009;  94 (2) 276-279
• 24 Pietrangelo A, Caleffi A, Henrion J et al.. Juvenile hemochromatosis associated with pathogenic mutations of adult hemochromatosis genes.  Gastroenterology. 2005;  128 (2) 470-479
• 25 Biasiotto G, Camaschella C, Forni G L, Polotti A, Zecchina G, Arosio P. New TFR2 mutations in young Italian patients with hemochromatosis.  Haematologica. 2008;  93 (2) 309-310
• 26 Hofmann W K, Tong X J, Ajioka R S, Kushner J P, Koeffler H P. Mutation analysis of transferrin-receptor 2 in patients with atypical hemochromatosis.  Blood. 2002;  100 (3) 1099-1100
• 27 Cunat S, Giansily-Blaizot M, Bismuth M CHU Montpellier AOI 2004 Working Group et al. Global sequencing approach for characterizing the molecular background of hereditary iron disorders.  Clin Chem. 2007;  53 (12) 2060-2069
• 28 Rivard S R, Lanzara C, Grimard D et al.. Autosomal dominant reticuloendothelial iron overload (HFE type 4) due to a new missense mutation in the FERROPORTIN 1 gene (SLC11A3) in a large French-Canadian family.  Haematologica. 2003;  88 (7) 824-826
• 29 Njajou O T, Vaessen N, Joosse M et al.. A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis.  Nat Genet. 2001;  28 (3) 213-214
• 30 Wallace D F, Clark R M, Harley H A, Subramaniam V N. Autosomal dominant iron overload due to a novel mutation of ferroportin1 associated with parenchymal iron loading and cirrhosis.  J Hepatol. 2004;  40 (4) 710-713
• 31 Arden K E, Wallace D F, Dixon J L et al.. A novel mutation in ferroportin1 is associated with haemochromatosis in a Solomon Islands patient.  Gut. 2003;  52 (8) 1215-1217
• 32 Del-Castillo-Rueda A, Moreno-Carralero M I, Alvarez-Sala-Walther L A et al.. Two novel mutations in the SLC40A1 and HFE genes implicated in iron overload in a Spanish man.  Eur J Haematol. 2011;  86 (3) 260-264
• 33 Viprakasit V, Merryweather-Clarke A T, Chinthammitr Y et al.. Molecular diagnosis of the first ferroportin mutation (C326Y) in the Far East causing a dominant form of inherited iron overload.  Blood. 2004;  104 (11) 3204 (ASH Annual Meeting Abstracts)
• 34 Lok C Y, Merryweather-Clarke A T, Viprakasit V et al.. Iron overload in the Asian community.  Blood. 2009;  114 (1) 20-25
• 35 Sham R L, Phatak P D, West C, Lee P, Andrews C, Beutler E. Autosomal dominant hereditary hemochromatosis associated with a novel ferroportin mutation and unique clinical features.  Blood Cells Mol Dis. 2005;  34 (2) 157-161
• 36 Wallace D F, Dixon J L, Ramm G A, Anderson G J, Powell L W, Subramaniam V N. A novel mutation in ferroportin implicated in iron overload.  J Hepatol. 2007;  46 (5) 921-926
• 37 Létocart E, Le Gac G, Majore S et al.. A novel missense mutation in SLC40A1 results in resistance to hepcidin and confirms the existence of two ferroportin-associated iron overload diseases.  Br J Haematol. 2009;  147 (3) 379-385
• 38 Mayr R, Griffiths W J, Hermann M et al.. Identification of mutations in SLC40A1 that affect ferroportin function and phenotype of human ferroportin iron overload.  Gastroenterology. 2011;  140 (7) 2056-2063, e1
• 39 Lee P, Promrat K, Mallette C, Flynn M, Beutler E. A juvenile hemochromatosis patient homozygous for a novel deletion of cDNA nucleotide 81 of hemojuvelin.  Acta Haematol. 2006;  115 (1–2) 123-127
• 40 Murugan R C, Lee P L, Kalavar M R, Barton J C. Early age-of-onset iron overload and homozygosity for the novel hemojuvelin mutation HJV R54X (exon 3; c.160A—> T) in an African American male of West Indies descent.  Clin Genet. 2008;  74 (1) 88-92
• 41 Jánosi A, Andrikovics H, Vas K et al.. Homozygosity for a novel nonsense mutation (G66X) of the HJV gene causes severe juvenile hemochromatosis with fatal cardiomyopathy.  Blood. 2005;  105 (1) 432
• 42 Lanzara C, Roetto A, Daraio F et al.. Spectrum of hemojuvelin gene mutations in 1q-linked juvenile hemochromatosis.  Blood. 2004;  103 (11) 4317-4321
• 43 Lee P L, Beutler E, Rao S V, Barton J C. Genetic abnormalities and juvenile hemochromatosis: mutations of the HJV gene encoding hemojuvelin.  Blood. 2004;  103 (12) 4669-4671
• 44 Wallace D F, Dixon J L, Ramm G A, Anderson G J, Powell L W, Subramaniam N. Hemojuvelin (HJV)-associated hemochromatosis: analysis of HJV and HFE mutations and iron overload in three families.  Haematologica. 2005;  90 (2) 254-255
• 45 Le Gac G, Scotet V, Ka C et al.. The recently identified type 2A juvenile haemochromatosis gene (HJV), a second candidate modifier of the C282Y homozygous phenotype.  Hum Mol Genet. 2004;  13 (17) 1913-1918
• 46 Daraio F, Ryan E, Gleeson F, Roetto A, Crowe J, Camaschella C. Juvenile hemochromatosis due to G320V/Q116X compound heterozygosity of hemojuvelin in an Irish patient.  Blood Cells Mol Dis. 2005;  35 (2) 174-176
• 47 Gehrke S G, Pietrangelo A, Kascák M et al.. HJV gene mutations in European patients with juvenile hemochromatosis.  Clin Genet. 2005;  67 (5) 425-428
• 48 de Diego C, Opazo S, Sánchez-Castaño A, Martínez-Castro P. New HJV mutation in a patient with hyperferritinemia and H63D homozygosity for the HFE gene.  Int J Hematol. 2007;  86 (4) 379-380
• 49 van Dijk B A, Kemna E H, Tjalsma H et al.. Effect of the new HJV-L165X mutation on penetrance of HFE.  Blood. 2007;  109 (12) 5525-5526
• 50 Klomp C, Abbes A P, Engel H. Gene symbol: HFE2a (HJV). Disease: juvenile hemochromatosis.  Hum Genet. 2005;  118 (3–4) 545-546
• 51 Aguilar-Martinez P, Lok C Y, Cunat S, Cadet E, Robson K, Rochette J. Juvenile hemochromatosis caused by a novel combination of hemojuvelin G320V/R176C mutations in a 5-year old girl.  Haematologica. 2007;  92 (3) 421-422
• 52 Ka C, Le Gac G, Letocart E, Gourlaouen I, Martin B, Férec C. Phenotypic and functional data confirm causality of the recently identified hemojuvelin p.r176c missense mutation.  Haematologica. 2007;  92 (9) 1262-1263
• 53 Biasiotto G, Roetto A, Daraio F et al.. Identification of new mutations of hepcidin and hemojuvelin in patients with HFE C282Y allele.  Blood Cells Mol Dis. 2004;  33 (3) 338-343
• 54 Koyama C, Hayashi H, Wakusawa S et al.. Three patients with middle-age-onset hemochromatosis caused by novel mutations in the hemojuvelin gene.  J Hepatol. 2005;  43 (4) 740-742
• 55 Huang F W, Rubio-Aliaga I, Kushner J P, Andrews N C, Fleming M D. Identification of a novel mutation (C321X) in HJV.  Blood. 2004;  104 (7) 2176-2177
• 56 Filali M, Le Jeunne C, Durand E et al.. Juvenile hemochromatosis HJV-related revealed by cardiogenic shock.  Blood Cells Mol Dis. 2004;  33 (2) 120-124
• 57 Nagayoshi Y, Nakayama M, Suzuki S et al.. A Q312X mutation in the hemojuvelin gene is associated with cardiomyopathy due to juvenile haemochromatosis.  Eur J Heart Fail. 2008;  10 (10) 1001-1006
• 58 Militaru M S, Popp R A, Trifa A P. Homozygous G320V mutation in the HJV gene causing juvenile hereditary haemochromatosis type A. A case report.  J Gastrointestin Liver Dis. 2010;  19 (2) 191-193
• 59 Brakensiek K, Fegbeutel C, Mälzer M, Strüber M, Kreipe H, Stuhrmann M. Juvenile hemochromatosis due to homozygosity for the G320V mutation in the HJV gene with fatal outcome.  Clin Genet. 2009;  76 (5) 493-495
• 60 Santos P C, Cançado R D, Pereira A C et al.. Hereditary hemochromatosis: mutations in genes involved in iron homeostasis in Brazilian patients.  Blood Cells Mol Dis. 2011;  46 (4) 302-307
• 61 Várkonyi J, Lueff S, Szucs N et al.. Hemochromatosis and hemojuvelin G320V homozygosity in a Hungarian woman.  Acta Haematol. 2010;  123 (3) 191-193
• 62 Zhou R-F, Ouyang J, Guo X et al.. Novel homozygous mutation (R329X) in the hemojuvelin gene is associated with hypogonadotrophic hypogonadism, diabetes mellitus and heart failure due to juvenile hemochromatosis.  Blood. 2009;  114 (22) 5102 (ASH Annual Meeting Abstracts)
• 63 Island M L, Jouanolle A M, Mosser A et al.. A new mutation in the hepcidin promoter impairs its BMP response and contributes to a severe phenotype in HFE related hemochromatosis.  Haematologica. 2009;  94 (5) 720-724
• 64 Matthes T, Aguilar-Martinez P, Pizzi-Bosman L et al.. Severe hemochromatosis in a Portuguese family associated with a new mutation in the 5′-UTR of the HAMP gene.  Blood. 2004;  104 (7) 2181-2183
• 65 Porto G, Roetto A, Daraio F et al.. A Portuguese patient homozygous for the −25G> A mutation of the HAMP promoter shows evidence of steady-state transcription but fails to up-regulate hepcidin levels by iron.  Blood. 2005;  106 (8) 2922-2923
• 66 Mendes A I, Ferro A, Martins R et al.. Non-classical hereditary hemochromatosis in Portugal: novel mutations identified in iron metabolism-related genes.  Ann Hematol. 2009;  88 (3) 229-234
• 67 Merryweather-Clarke A T, Cadet E, Bomford A et al.. Digenic inheritance of mutations in HAMP and HFE results in different types of haemochromatosis.  Hum Mol Genet. 2003;  12 (17) 2241-2247
• 68 Jacolot S, Le Gac G, Scotet V, Quere I, Mura C, Ferec C. HAMP as a modifier gene that increases the phenotypic expression of the HFE pC282Y homozygous genotype.  Blood. 2004;  103 (7) 2835-2840
• 69 Roetto A, Daraio F, Porporato P et al.. Screening hepcidin for mutations in juvenile hemochromatosis: identification of a new mutation (C70R).  Blood. 2004;  103 (6) 2407-2409
• 70 Majore S, Binni F, Pennese A, De Santis A, Crisi A, Grammatico P. HAMP gene mutation c.208T> C (p.C70R) identified in an Italian patient with severe hereditary hemochromatosis.  Hum Mutat. 2004;  23 (4) 400
• 71 Delatycki M B, Allen K J, Gow P et al.. A homozygous HAMP mutation in a multiply consanguineous family with pseudo-dominant juvenile hemochromatosis.  Clin Genet. 2004;  65 (5) 378-383
• 72 Pietrangelo A. The ferroportin disease.  Blood Cells Mol Dis. 2004;  32 (1) 131-138
• 73 Pietrangelo A. Hereditary hemochromatosis—a new look at an old disease.  N Engl J Med. 2004;  350 (23) 2383-2397
• 74 De Domenico I, Ward D M, Langelier C et al.. The molecular mechanism of hepcidin-mediated ferroportin down-regulation.  Mol Biol Cell. 2007;  18 (7) 2569-2578
• 75 Plattner H C, Nussbaumer T, Rywlin A. [Juvenile and familial hemochromatosis with endocrinomyocardiac syndrome].  Helv Med Acta. 1951;  18 (4-5) 499-502
• 76 Lamon J M, Marynick S P, Roseblatt R, Donnelly S. Idiopathic hemochromatosis in a young female. A case study and review of the syndrome in young people.  Gastroenterology. 1979;  76 (1) 178-183
• 77 Cazzola M, Ascari E, Barosi G et al.. Juvenile idiopathic haemochromatosis: a life-threatening disorder presenting as hypogonadotropic hypogonadism.  Hum Genet. 1983;  65 (2) 149-154
• 78 Kelly A L, Rhodes D A, Roland J M, Schofield P, Cox T M. Hereditary juvenile haemochromatosis: a genetically heterogeneous life-threatening iron-storage disease.  QJM. 1998;  91 (9) 607-618
• 79 Rivard S R, Mura C, Simard H et al.. Clinical and molecular aspects of juvenile hemochromatosis in Saguenay-Lac-Saint-Jean (Quebec, Canada).  Blood Cells Mol Dis. 2000;  26 (1) 10-14
• 80 De Gobbi M, Roetto A, Piperno A et al.. Natural history of juvenile haemochromatosis.  Br J Haematol. 2002;  117 (4) 973-979
• 81 Devalia V, Carter K, Walker A P et al.. Autosomal dominant reticuloendothelial iron overload associated with a 3-base pair deletion in the ferroportin 1 gene (SLC11A3).  Blood. 2002;  100 (2) 695-697
• 82 Wallace D F, Pedersen P, Dixon J L et al.. Novel mutation in ferroportin1 is associated with autosomal dominant hemochromatosis.  Blood. 2002;  100 (2) 692-694
• 83 Roetto A, Merryweather-Clarke A T, Daraio F et al.. A valine deletion of ferroportin 1: a common mutation in hemochromastosis type 4.  Blood. 2002;  100 (2) 733-734
• 84 Cazzola M, Cremonesi L, Papaioannou M et al.. Genetic hyperferritinaemia and reticuloendothelial iron overload associated with a three base pair deletion in the coding region of the ferroportin gene (SLC11A3).  Br J Haematol. 2002;  119 (2) 539-546
• 85 Hetet G, Devaux I, Soufir N, Grandchamp B, Beaumont C. Molecular analyses of patients with hyperferritinemia and normal serum iron values reveal both L ferritin IRE and 3 new ferroportin (SLC11A3) mutations.  Blood. 2003;  102 (5) 1904-1910
• 86 Jouanolle A M, Douabin-Gicquel V, Halimi C et al.. Novel mutation in ferroportin 1 gene is associated with autosomal dominant iron overload.  J Hepatol. 2003;  39 (2) 286-289
• 87 Zoller H, McFarlane I, Theurl I et al.. Primary iron overload with inappropriate hepcidin expression in V162del ferroportin disease.  Hepatology. 2005;  42 (2) 466-472
• 88 Cremonesi L, Forni G L, Soriani N et al.. Genetic and clinical heterogeneity of ferroportin disease.  Br J Haematol. 2005;  131 (5) 663-670
• 89 Subramaniam V N, Wallace D F, Dixon J L, Fletcher L M, Crawford D H. Ferroportin disease due to the A77D mutation in Australia.  Gut. 2005;  54 (7) 1048-1049
• 90 Koyama C, Wakusawa S, Hayashi H et al.. A Japanese family with ferroportin disease caused by a novel mutation of SLC40A1 gene: hyperferritinemia associated with a relatively low transferrin saturation of iron.  Intern Med. 2005;  44 (9) 990-993
• 91 Bach V, Remacha A, Altés A, Barceló M J, Molina M A, Baiget M. Autosomal dominant hereditary hemochromatosis associated with two novel ferroportin 1 mutations in Spain.  Blood Cells Mol Dis. 2006;  36 (1) 41-45
• 92 De Domenico I, McVey Ward D, Nemeth E et al.. Molecular and clinical correlates in iron overload associated with mutations in ferroportin.  Haematologica. 2006;  91 (8) 1092-1095
• 93 Girelli D, De Domenico I, Bozzini C et al.. Clinical, pathological, and molecular correlates in ferroportin disease: a study of two novel mutations.  J Hepatol. 2008;  49 (4) 664-671
• 94 Pelucchi S, Mariani R, Salvioni A et al.. Novel mutations of the ferroportin gene (SLC40A1): analysis of 56 consecutive patients with unexplained iron overload.  Clin Genet. 2008;  73 (2) 171-178
• 95 Mayr R, Janecke A R, Schranz M et al.. Ferroportin disease: a systematic meta-analysis of clinical and molecular findings.  J Hepatol. 2010;  53 (5) 941-949
• 96 McDonald C J, Wallace D F, Ostini L, Bell S J, Demediuk B, Subramaniam V N. G80S-linked ferroportin disease: classical ferroportin disease in an Asian family and reclassification of the mutant as iron transport defective.  J Hepatol. 2011;  54 (3) 538-544
• 97 Saja K, Bignell P, Robson K, Provan D. A novel missense mutation c.470 A> C (p.D157A) in the SLC40A1 gene as a cause of ferroportin disease in a family with hyperferritinaemia.  Br J Haematol. 2010;  149 (6) 914-916
• 98 Le Lan C, Mosser A, Ropert M et al.. Sex and acquired cofactors determine phenotypes of ferroportin disease.  Gastroenterology. 2011;  140 (4) 1199-1207 e1-e2
• 99 Lim F L, Dooley J S, Roques A W, Grellier L, Dhillon A P, Walker A P. Hepatic iron concentration, fibrosis and response to venesection associated with the A77D and V162del “loss of function” mutations in ferroportin disease.  Blood Cells Mol Dis. 2008;  40 (3) 328-333
• 100 Corradini E, Montosi G, Ferrara F et al.. Lack of enterocyte iron accumulation in the ferroportin disease.  Blood Cells Mol Dis. 2005;  35 (3) 315-318
• 101 Mougiou A, Pietrangelo A, Caleffi A, Kourakli A, Karakantza M, Zoumbos N. G80S-linked ferroportin disease: the first clinical description in a Greek family.  Blood Cells Mol Dis. 2008;  41 (1) 138-139
• 102 Speletas M, Kioumi A, Loules G et al.. Analysis of SLC40A1 gene at the mRNA level reveals rapidly the causative mutations in patients with hereditary hemochromatosis type IV.  Blood Cells Mol Dis. 2008;  40 (3) 353-359
• 103 Wallace D F, Browett P, Wong P, Kua H, Ameratunga R, Subramaniam V N. Identification of ferroportin disease in the Indian subcontinent.  Gut. 2005;  54 (4) 567-568
• 104 Morris T J, Litvinova M M, Ralston D, Mattman A, Holmes D, Lockitch G. A novel ferroportin mutation in a Canadian family with autosomal dominant hemochromatosis.  Blood Cells Mol Dis. 2005;  35 (3) 309-314
• 105 Relvas L, Claro M T, Bento M C, Ribeiro M L. Novel human pathological mutations. Gene symbol: SLC40A1. Disease: haemochromatosis, type 4.  Hum Genet. 2009;  125 (3) 338
• 106 Gordeuk V R, Caleffi A, Corradini E et al.. Iron overload in Africans and African-Americans and a common mutation in the SCL40A1 (ferroportin 1) gene.  Blood Cells Mol Dis. 2003;  31 (3) 299-304
• 107 Beutler E, Barton J C, Felitti V J et al.. Ferroportin 1 (SCL40A1) variant associated with iron overload in African-Americans.  Blood Cells Mol Dis. 2003;  31 (3) 305-309
• 108 Zaahl M G, Merryweather-Clarke A T, Kotze M J, van der Merwe S, Warnich L, Robson K J. Analysis of genes implicated in iron regulation in individuals presenting with primary iron overload.  Hum Genet. 2004;  115 (5) 409-417
• 109 Lee P L, Gelbart T, West C, Barton J C. SLC40A1 c.1402G—> a results in aberrant splicing, ferroportin truncation after glycine 330, and an autosomal dominant hemochromatosis phenotype.  Acta Haematol. 2007;  118 (4) 237-241
• 110 Griffiths W J, Mayr R, McFarlane I et al.. Clinical presentation and molecular pathophysiology of autosomal dominant hemochromatosis caused by a novel ferroportin mutation.  Hepatology. 2010;  51 (3) 788-795
• 111 Pietrangelo A, Corradini E, Ferrara F et al.. Magnetic resonance imaging to identify classic and nonclassic forms of ferroportin disease.  Blood Cells Mol Dis. 2006;  37 (3) 192-196
• 112 Miyajima H, Nishimura Y, Mizoguchi K, Sakamoto M, Shimizu T, Honda N. Familial apoceruloplasmin deficiency associated with blepharospasm and retinal degeneration.  Neurology. 1987;  37 (5) 761-767
• 113 Yoshida K, Furihata K, Takeda S et al.. A mutation in the ceruloplasmin gene is associated with systemic hemosiderosis in humans.  Nat Genet. 1995;  9 (3) 267-272
• 114 Harris Z L, Takahashi Y, Miyajima H, Serizawa M, MacGillivray R T, Gitlin J D. Aceruloplasminemia: molecular characterization of this disorder of iron metabolism.  Proc Natl Acad Sci U S A. 1995;  92 (7) 2539-2543
• 115 Kono S, Suzuki H, Takahashi K et al.. Hepatic iron overload associated with a decreased serum ceruloplasmin level in a novel clinical type of aceruloplasminemia.  Gastroenterology. 2006;  131 (1) 240-245
• 116 Yang F, Naylor S L, Lum J B et al.. Characterization, mapping, and expression of the human ceruloplasmin gene.  Proc Natl Acad Sci U S A. 1986;  83 (10) 3257-3261
• 117 Harris Z L, Durley A P, Man T K, Gitlin J D. Targeted gene disruption reveals an essential role for ceruloplasmin in cellular iron efflux.  Proc Natl Acad Sci U S A. 1999;  96 (19) 10812-10817
• 118 De Domenico I, Ward D M, di Patti M C et al.. Ferroxidase activity is required for the stability of cell surface ferroportin in cells expressing GPI-ceruloplasmin.  EMBO J. 2007;  26 (12) 2823-2831
• 119 Miyajima H. Aceruloplasminemia. In: Pagon R A, Bird T D, Dolan C R, Stephens K, eds. Seattle, WA: GeneReviews; 1993
• 120 Miyajima H, Takahashi Y, Kamata T, Shimizu H, Sakai N, Gitlin J D. Use of desferrioxamine in the treatment of aceruloplasminemia.  Ann Neurol. 1997;  41 (3) 404-407
• 121 Finkenstedt A, Wolf E, Höfner E et al.. Hepatic but not brain iron is rapidly chelated by deferasirox in aceruloplasminemia due to a novel gene mutation.  J Hepatol. 2010;  53 (6) 1101-1107
• 122 Heilmeyer L, Keller W, Vivell O et al.. [Congenital atransferrinemia in a 7-year-old girl].  Dtsch Med Wochenschr. 1961;  86 1745-1751
• 123 Hayashi A, Wada Y, Suzuki T, Shimizu A. Studies on familial hypotransferrinemia: unique clinical course and molecular pathology.  Am J Hum Genet. 1993;  53 (1) 201-213
• 124 Beutler E, Gelbart T, Lee P, Trevino R, Fernandez M A, Fairbanks V F. Molecular characterization of a case of atransferrinemia.  Blood. 2000;  96 (13) 4071-4074
• 125 Knisely A S, Gelbart T, Beutler E. Molecular characterization of a third case of human atransferrinemia.  Blood. 2004;  104 (8) 2607
• 126 Aslan D, Crain K, Beutler E. A new case of human atransferrinemia with a previously undescribed mutation in the transferrin gene.  Acta Haematol. 2007;  118 (4) 244-247
• 127 Chen C, Wen S, Tan X. Molecular analysis of a novel case of congenital atransferrinemia.  Acta Haematol. 2009;  122 (1) 27-28
• 128 Shamsian B S, Rezaei N, Arzanian M T, Alavi S, Khojasteh O, Eghbali A. Severe hypochromic microcytic anemia in a patient with congenital atransferrinemia.  Pediatr Hematol Oncol. 2009;  26 (5) 356-362
• 129 Andrews N C. The iron transporter DMT1.  Int J Biochem Cell Biol. 1999;  31 (10) 991-994
• 130 Mims M P, Guan Y, Pospisilova D et al.. Identification of a human mutation of DMT1 in a patient with microcytic anemia and iron overload.  Blood. 2005;  105 (3) 1337-1342
• 131 Lam-Yuk-Tseung S, Camaschella C, Iolascon A, Gros P. A novel R416C mutation in human DMT1 (SLC11A2) displays pleiotropic effects on function and causes microcytic anemia and hepatic iron overload.  Blood Cells Mol Dis. 2006;  36 (3) 347-354
• 132 Beaumont C, Delaunay J, Hetet G, Grandchamp B, de Montalembert M, Tchernia G. Two new human DMT1 gene mutations in a patient with microcytic anemia, low ferritinemia, and liver iron overload.  Blood. 2006;  107 (10) 4168-4170
• 133 Iolascon A, d'Apolito M, Servedio V, Cimmino F, Piga A, Camaschella C. Microcytic anemia and hepatic iron overload in a child with compound heterozygous mutations in DMT1 (SCL11A2).  Blood. 2006;  107 (1) 349-354
• 134 Iolascon A, Camaschella C, Pospisilova D, Piscopo C, Tchernia G, Beaumont C. Natural history of recessive inheritance of DMT1 mutations.  J Pediatr. 2008;  152 (1) 136-139
• 135 Blanco E, Kannengiesser C, Grandchamp B, Tasso M, Beaumont C. Not all DMT1 mutations lead to iron overload.  Blood Cells Mol Dis. 2009;  43 (2) 199-201
• 136 Pospisilova D, Mims M P, Nemeth E, Ganz T, Prchal J T. DMT1 mutation: response of anemia to darbepoetin administration and implications for iron homeostasis.  Blood. 2006;  108 (1) 404-405
• 137 Iolascon A, De Falco L. Mutations in the gene encoding DMT1: clinical presentation and treatment.  Semin Hematol. 2009;  46 (4) 358-370
• 138 Kato J, Fujikawa K, Kanda M et al.. A mutation, in the iron-responsive element of H ferritin mRNA, causing autosomal dominant iron overload.  Am J Hum Genet. 2001;  69 (1) 191-197
• 139 Vanoaica L, Darshan D, Richman L, Schümann K, Kühn L C. Intestinal ferritin H is required for an accurate control of iron absorption.  Cell Metab. 2010;  12 (3) 273-282
• 140 Rund D, Rachmilewitz E. Beta-thalassemia.  N Engl J Med. 2005;  353 (11) 1135-1146
• 141 Cazzola M, Barosi G, Gobbi P G, Invernizzi R, Riccardi A, Ascari E. Natural history of idiopathic refractory sideroblastic anemia.  Blood. 1988;  71 (2) 305-312
• 142 Di Marco V, Capra M, Angelucci E Italian Society for the Study of Thalassemia and Haemoglobinopathies; Italian Association for the Study of the Liver et al. Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel.  Blood. 2010;  116 (16) 2875-2883
• 143 Campuzano V, Montermini L, Moltò M D et al.. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion.  Science. 1996;  271 (5254) 1423-1427
• 144 Boddaert N, Le Quan Sang K H, Rötig A et al.. Selective iron chelation in Friedreich ataxia: biologic and clinical implications.  Blood. 2007;  110 (1) 401-408
• 145 Porter J B, Shah F T. Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies.  Hematol Oncol Clin North Am. 2010;  24 (6) 1109-1130
• 146 Wood J C, Noetzli L. Cardiovascular MRI in thalassemia major.  Ann N Y Acad Sci. 2010;  1202 173-179
• 147 Babitt J L, Lin H Y. Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD.  Am J Kidney Dis. 2010;  55 (4) 726-741
• 148 Pietrangelo A. Iron in NASH, chronic liver diseases and HCC: how much iron is too much?.  J Hepatol. 2009;  50 (2) 249-251
• 149 Puy H, Gouya L, Deybach J C. Porphyrias.  Lancet. 2010;  375 (9718) 924-937
• 150 Elder G H, Lee G B, Tovey J A. Decreased activity of hepatic uroporphyrinogen decarboxylase in sporadic porphyria cutanea tarda.  N Engl J Med. 1978;  299 (6) 274-278
• 151 Sampietro M, Piperno A, Lupica L et al.. High prevalence of the His63Asp HFE mutation in Italian patients with porphyria cutanea tarda.  Hepatology. 1998;  27 (1) 181-184
• 152 Fargion S, Fracanzani A L. Prevalence of hepatitis C virus infection in porphyria cutanea tarda.  J Hepatol. 2003;  39 (4) 635-638
• 153 Chemmanur A T, Bonkovsky H L. Hepatic porphyrias: diagnosis and management.  Clin Liver Dis. 2004;  8 (4) 807-838 viii
• 154 Epstein J H, Redeker A G. Porphyria cutanea tarda. A study of the effect of phlebotomy.  N Engl J Med. 1968;  279 (24) 1301-1304
• 155 Walker A R, Arvidsson U B. Iron intake and haemochromatosis in the Bantu.  Nature. 1950;  166 (4219) 438-439
• 156 Gordeuk V R, McLaren C E, MacPhail A P, Deichsel G, Bothwell T H. Associations of iron overload in Africa with hepatocellular carcinoma and tuberculosis: Strachan's 1929 thesis revisited.  Blood. 1996;  87 (8) 3470-3476
• 157 Bothwell T H, Seftel H C, Jacobs P, Torrance J D, Baumslag N. Iron overload in Bantu subjects. Studies on the availability of iron in Bantu beer.  Am J Clin Nutr. 1964;  14 47-51
• 158 Gordeuk V, Mukiibi J, Hasstedt S J et al.. Iron overload in Africa. Interaction between a gene and dietary iron content.  N Engl J Med. 1992;  326 (2) 95-100
• 159 Mandishona E, MacPhail A P, Gordeuk V R et al.. Dietary iron overload as a risk factor for hepatocellular carcinoma in Black Africans.  Hepatology. 1998;  27 (6) 1563-1566
• 160 Knisely A S, Mieli-Vergani G, Whitington P F. Neonatal hemochromatosis.  Gastroenterol Clin North Am. 2003;  32 (3) 877-889 vi-vii
• 161 Whitington P F, Hibbard J U. High-dose immunoglobulin during pregnancy for recurrent neonatal haemochromatosis.  Lancet. 2004;  364 (9446) 1690-1698
• 162 Pan X, Kelly S, Melin-Aldana H, Malladi P, Whitington P F. Novel mechanism of fetal hepatocyte injury in congenital alloimmune hepatitis involves the terminal complement cascade.  Hepatology. 2010;  51 (6) 2061-2068
• 163 Whitington P F, Kelly S. Outcome of pregnancies at risk for neonatal hemochromatosis is improved by treatment with high-dose intravenous immunoglobulin.  Pediatrics. 2008;  121 (6) e1615-e1621
• 164 Rand E B, Karpen S J, Kelly S et al.. Treatment of neonatal hemochromatosis with exchange transfusion and intravenous immunoglobulin.  J Pediatr. 2009;  155 (4) 566-571
• 165 Whitington P F. Neonatal hemochromatosis: a congenital alloimmune hepatitis.  Semin Liver Dis. 2007;  27 (3) 243-250